PC
ALDR

Polar Capital’s Alder Biopharmaceuticals ALDR Stock Holding History

Polar Capital’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-250,000
Closed -$2.86M – 284
2017
Q4 		$2.86M Buy
+250,000
New +$2.79M 0.03% 226
2017
Q1 		– Sell
-100,000
Closed -$2.08M – 280
2016
Q4 		$2.08M Buy
100,000
+25,000
+33% +$650K 0.03% 227
2016
Q3 		$2.46M Hold
75,000
– – 0.04% 210
2016
Q2 		$1.87M Buy
+75,000
New +$2.03M 0.04% 226
2015
Q2 		– Sell
-128,461
Closed -$3.71M – 312
2015
Q1 		$3.71M Buy
128,461
+102,865
+402% +$2.82M 0.07% 188
2014
Q4 		$745K Buy
+25,596
New +$459K 0.01% 245

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Polar Capital's ALDR Position: Q1 2018 in Review

Polar Capital sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 250,000 shares — an estimated $2.86M sold.

Polar Capital first reported a position in ALDR in Q4 2014 and held it in 6 quarters. The position peaked at $3.71M in Q1 2015. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • Polar Capital reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Polar Capital sold 250,000 Alder Biopharmaceuticals shares in Q1 2018, an estimated $2.86M.
  • Polar Capital first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 6 quarters.
  • Polar Capital's Alder Biopharmaceuticals position peaked at $3.71M in Q1 2015.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Polar Capital's 13F filing for Q1 2018, filed 15 May 2018.